drugset / Trial / NCT03011008
Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to investigate the therapeutic effect of Liraglutide on autoimmune diabetes.
Timeline
- Start
- 2017-01
- Primary completion
- 2020-12
- Completion
- 2021-06
Publications
- Background Rondas D, D'Hertog W, Overbergh L, Mathieu C. Glucagon-like peptide-1: modulator of beta-cell dysfunction and death. Diabetes Obes Metab. 2013 Sep;15 Suppl 3:185-92. doi: 10.1111/dom.12165.
- Background Chang TJ, Tseng HC, Liu MW, Chang YC, Hsieh ML, Chuang LM. Glucagon-like peptide-1 prevents methylglyoxal-induced apoptosis of beta cells through improving mitochondrial function and suppressing prolonged AMPK activation. Sci Rep. 2016 Mar 21;6:23403. doi: 10.1038/srep23403.
- Background Mathieu C, Gillard P. Arresting type 1 diabetes after diagnosis: GAD is not enough. Lancet. 2011 Jul 23;378(9788):291-2. doi: 10.1016/S0140-6736(11)60978-1. Epub 2011 Jun 27. No abstract available.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Liraglutide | Peptide | 1.2 mg | — |
| Background | Insulin | Protein / enzyme biologic | — | Other |